Treatments for patients with genotype 1 chronic hepatitis C: a review of evidence-based guidelines

Record ID 32015000245
Authors' recommendations: The two newest CHC drugs, simeprevir and sofosbuvir, in combination with each other or with other agents (PR, ribavirin or daclatasvir) are currently the recommended treatments for various sub-populations of patients with genotype 1 CHC according to the most recent guidelines. These recommendations are based on randomized controlled trial (RCT) and non-RCT evidence and do not take into consideration cost and cost-effectiveness.
Project Status: Completed
Year Published: 2014
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Antiviral Agents
  • Drug Therapy, Combination
  • Hepatitis C, Chronic
  • Sofosbuvir
  • Simeprevir
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.